Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

<i>Background and Objectives</i>: HER2-positive breast cancer accounts for approximately 20–30% of all breast cancer cases and is associated with aggressive tumor behavior. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, is a standard second-line therapy for pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim, Yunus Emre Altintas, Deniz Isik, Heves Surmeli, Hatice Odabas, Seval Ay, Tugba Basoglu, Nedim Turan
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Medicina
Subjects:
HER2-positive breast cancer
trastuzumab emtansine
T-DM1
immunohistochemistry
progression-free survival
overall survival
Online Access:https://www.mdpi.com/1648-9144/61/5/819
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items